Trust in the FDA Crumbles: Why Transparency on Food and Drugs Is Non‑Negotiable

Trust in the FDA: The Numbers Tell a Story

Recent Reuters polling shows ↓ 48% of Americans still trust the agency, down from ↑ 75% two years ago. The erosion stems not from perceived incompetence but from doubts about political independence, a sentiment echoed in a Harvard Bloomberg health‑policy survey.

“Science is the nation’s highest expression,” Louis Pasteur warned 140 years ago; the FDA must live up to that legacy.

Patients, investors, and innovators all hinge on a regulator that applies evidence‑based standards consistently. When the agency reverses course—such as the sudden shift on Moderna’s mRNA flu candidate—companies scramble, trial designs stall, and the broader innovation pipeline shivers.

Key cases that spotlight predictability

Therapies like Replimune’s melanoma drug, uniQure’s Huntington gene therapy, and Regenxbio’s Hunter syndrome treatment have each faced questions about whether the FDA upheld the evidentiary benchmarks promised during expedited review. Critics argue that real‑world evidence and external expert input were sidelined, fueling concerns over transparency.

Under Acting Commissioner Kyle Diamantas, J.D., the agency has reopened several high‑profile reviews. These actions are not capitulations; they are an opportunity to demonstrate that the FDA can correct course, explain its rationale, and reaffirm scientific integrity.

A modern regulator must also master 21st‑century technologies—AI‑driven diagnostics, digital therapeutics, and adaptive trial platforms. That demands upgraded IT infrastructure, interoperable data streams, and robust post‑market surveillance that can flag safety signals across drugs, devices, foods, and even supplements.

Food safety, the “F” in FDA, deserves equal focus. Recent cyclosporiasis outbreaks underscore the need for rapid, data‑rich inspections and transparent communication, especially as the nation pursues a “Make America Healthy Again” agenda.

Looking ahead, the next commissioner should be chosen for scientific rigor, operational competence, and an unwavering commitment to independence—not ideology. Clear communication with Congress, industry, patient groups, and the public will be essential to rebuild the trust eroded during the pandemic era.

Analysis by: Elena Rostova

Socio-Economic Trends Analyst